CD8+ T Lymphocytes in Pituitary Neuroendocrine Tumors: Friend or Foe?
Cells · 19.06.2026 · 15 (12) · 1115
DOI: 10.3390/cells15121115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 19.06.2026. Verfasst von Valeria-Nicoleta Nastase und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microscopic Morphology/Histology, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Pituitary Neoplasms, Neuroendocrine Tumors. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The tumor immune microenvironment, particularly the role of cytotoxic CD8+ T lymphocytes, is crucial in cancer progression but remains poorly understood in pituitary neuroendocrine tumors (PitNETs). The significance of CD8+ cell infiltration varies across PitNET subtypes, suggesting a complex interplay with tumor cell lineage. This study aimed to characterize the distribution of CD8+ tumor-infiltrating lymphocytes across different PitNET subtypes defined by the current WHO classification and to explore their association with clinicopathological features.
Methods
We conducted a retrospective study on 40 surgically resected PitNETs. All cases were classified based on immunohistochemical expression of pituitary hormones and lineage-specific transcription factors (PIT-1, TPIT, SF-1). CD8+ lymphocyte density was quantified using immunohistochemistry and calculated as cells/mm2. Exploratory statistical analysis was performed based on non-parametric tests to compare CD8+ cell density across tumor subtypes and with parameters like tumor size, invasiveness (Knosp grade), and proliferation index (Ki-67). Findings are to be treated as observational trends.
Results
The highest density of CD8+ lymphocytes was observed in plurihormonal PIT-1-positive tumors [17.61 cells/mm2 (IQR: 17.61–60.36)], followed by somatotroph [13.2 (6.6–15.72)] and mammosomatotroph [13.83 (0–21.38)] tumors. A difference in CD8+ density was found between PIT-1-positive and PIT-1-negative tumors (n1 = 34, n2 = 6, U = 49.5, pexact = 0.050, r = 0.33); the medium effect size indicates a possible lineage-related trend. Another difference was observed between SF-1-positive and SF-1-negative tumors (p = 0.025), with SF-1 lineage tumors showing the lowest infiltration. No correlations were found between CD8+ density and tumor size, Knosp grade, or Ki-67 index.
Conclusions
The distribution of intratumoral CD8+ T lymphocytes in PitNETs is highly heterogeneous and appears to be strongly dictated by the transcription factor-defined tumor lineage rather than by traditional clinicopathological markers of aggressiveness. PIT-1 lineage tumors harbor a more active immune microenvironment, while SF-1 lineage tumors are relatively ‘immune-poor’. These findings highlight the immunological diversity of PitNETs and support further investigation of the tumor immune landscape. Collaborative multi-institutional studies are required to validate these trends.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microscopic Morphology/Histology, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
- Angiogenesis Research Centre, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
- "C. I. Parhon" National Institute of Endocrinology, 011683 Bucharest, Romania.
- Endocrinology Department, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
- Municipal Emergency Hospital, 300041 Timisoara, Romania.
- Department of Second Internal Medicine-Diabetes, Nutrition, Metabolic Diseases, and Systemic Rheumatology, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
ORCID-Profile: Amalia Raluca Ceausu, Roxana Ioana Dumitriu-Stan, Flavia Zara, Oana Albai, Bogdan Timar
Zitieren
APA
Nastase, V. N., Ceausu, A. R., Burcea, I. F., Dumitriu-Stan, R. I., Gaje, P. N., Zara, F., Raica, M., Albai, O., Poiana, C., & Timar, B. (2026). CD8+ T Lymphocytes in Pituitary Neuroendocrine Tumors: Friend or Foe?. Cells, 15(12), 1115. https://doi.org/10.3390/cells15121115
Vancouver
Nastase VN, Ceausu AR, Burcea IF, Dumitriu-Stan RI, Gaje PN, Zara F, et al. CD8+ T Lymphocytes in Pituitary Neuroendocrine Tumors: Friend or Foe?. Cells. 2026;15(12):1115. doi:10.3390/cells15121115
BibTeX
@article{Nastase2026,
author = {Nastase, Valeria-Nicoleta and Ceausu, Amalia Raluca and Burcea, Iulia Florentina and Dumitriu-Stan, Roxana Ioana and Gaje, Pusa Nela and Zara, Flavia and Raica, Marius and Albai, Oana and Poiana, Catalina and Timar, Bogdan},
title = {CD8+ T Lymphocytes in Pituitary Neuroendocrine Tumors: Friend or Foe?},
journal = {Cells},
year = {2026},
volume = {15},
number = {12},
pages = {1115},
doi = {10.3390/cells15121115}
}
EUVIMED